Hopp til hovedinnhold

Amyotrofisk lateralsklerose (ALS)

Sist revidert:
Sist revidert av:

Definisjon:
Progressiv nevrodegenerativ sykdom som selektivt rammer de motoriske nevroner på alle nivå - i ryggmarg, hjernestamme og motoriske cortex
Forekomst:
Insidensen er ca. 1,5-2,5 nye tilfeller pr. 100.000 innbyggere pr år
Symptomer:
Begynner oftest asymmetrisk og i ekstremitetene. Typiske tidlige symptomer er svakhet og klossethet i en hånd, etter hvert utvikles atrofi av muskulatur i hånden og armen
Funn:
Tidlige kliniske funn kan være atrofisk kraftsvekkelse, ofte først i hånd og armer, lett spastisitet i armer og bein, generalisert hyperrefleksi
Diagnostikk:
Andre undersøkelser bortsett fra EMG utføres primært for å utelukke annen sykdom
Behandling:
Det finnes ingen kurativ behandling, som derfor er symptomatisk og lindrende
  • Nasjonal kompetanse­tjeneste for hjemmerespirator­behandling - NKH - nettside 
  1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1603471 DOI  
  2. Ola Nakken: “Epidemiology of Amyotrophic Lateral Sclerosis: A population-based study in Norway”. Doktorgradsavhandling, Ahus. 12. februar 2020. www.med.uio.no  
  3. Ince PG and Codd GA. Return of the cycad hypothesis: does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Neuropathol Appl Neurobiol 2005; 31: 345-53. PubMed  
  4. McDermott CJ. Amyotrophic lateral sclerosis. BestPractice, last updated March 2020.
  5. Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, Giannini F, Mandrioli J, Mora G, Sabatelli M; the ITALSGEN Consortium,, Ajmone C, Mastro E, Pain D, Mandich P, Penco S, Restagno G, Zollino M, Surbone A. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014. pmid: 23833266 PubMed  
  6. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD001447. DOI: 10.1002/14651858.CD001447.pub3. DOI  
  7. Orrell RW, Lane RJM, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002829. DOI: 10.1002/14651858.CD002829.pub4. DOI  
  8. Colman E, Szarfman A, Wyeth J et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA’s spontaneous adverse event reporting system. United States Food and Drug 2008; : DOI: 10.1002/pds.1643. DOI  
  9. Gadoth A, Nefussy B, Bleiberg M, et al. Transglutaminase 6 antibodies in the serum of patients with amyotrophic lateral sclerosis. JAMA Neurol 2015; 72: 676-81. pmid:25867286 PubMed  
  10. Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ.. The cognitive profile of ALS: a systematic review and meta-analysis update.. J Neurol Neurosurg Psychiatry 2015. pmid:26283685 PubMed  
  11. Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurol 2015; 14: 435-42. pmid:25728958 PubMed  
  12. Batty GD, Gale CR. Pre-Morbid Risk Factors for Amyotrophic Lateral Sclerosis: Prospective Cohort Study. Clin Epidemiol. 2021 Oct 7;13:941-947. . PMID: 34675682. PubMed  
  13. Mattsson P, Lönnstedt I, Nygren I, Askmark H. Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age. J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):390-4. PubMed  
  14. World Federation of Neurology Research Group on Motor Neuron Diseases, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm (accessed Feb 18, 2007).
  15. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis .Eur J Neurol. 2012 Mar;19(3):360-75. doi: 10.1111/j.1468-1331.2011.03501.x. DOI  
  16. Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):303-309. Epub 2019 Mar 20. PMID: 30892087. PubMed  
  17. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66: 647-53. Neurology  
  18. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD004429. DOI: 10.1002/14651858.CD004429.pub2. DOI  
  19. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No.: CD003217. DOI: 10.1002/14651858.CD003217.pub5. The Cochrane Library  
  20. Chiò A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 2014;13(12):1228-1240. doi:10.1016/S1474-4422(14)70167-X DOI  
  21. Van Laere K1, Vanhee A2, Verschueren J3, De Coster L3, Driesen A2, Dupont P2, Robberecht W4, Van Damme P4. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014; May;71(5): 553-61. pmid:24615479 PubMed  
  22. Cosgrove J, Jamieson S, Chowdhury FU. Teaching NeuroImages: Hypometabolism of the primary motor cortex in primary lateral sclerosis: The stripe sign. Neurology 2015;84(24):e206. doi:26078407
  23. Leirvik A, Liverød M, Holmøy T. Livskvalitet hos pasienter med amyotrofisk lateral sklerose. Tidsskr Nor Lægeforen 2006; 126: 2520-2. PubMed  
  24. Holmøy T, Worren T. Kommunikasjonshjelpemidler ved amyotrofisk lateral sklerose. Tidsskr Nor Lægeforen 2006; 126: 2523-5. PubMed  
  25. Beauverd M, Mitchell JD, Wokke JHJ, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD002064. The Cochrane Library  
  26. Holmøy T, Ljøstad U, Mygland Å. Amyotrofisk lateral sklerose. Nevro-NEL, sist oppdatert 12.10.2020. nevrologi.legehandboka.no  
  27. Banfi P, Ticozzi N, Lax A, Guidugli GA, Nicolini A, Silani V. A Review of Options for Treating Sialorrhea in Amyotrophic Lateral Sclerosis. Respir Care 2014. pmid:25228780 PubMed  
  28. Kubler A, Nijboer F, Mellinger J, et al. Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface. Neurology 2005; 64: 1775-7. Neurology  
  29. Morrow B, Zampoli M, van Aswegen H, Argent A. Mechanical insufflation-exsufflation for people with neuromuscular disorders. Cochrane Database of Syst Rev. 2013, Issue 12. Art. No.: CD010044. DOI: 10.1002/14651858.CD010044.pub2. DOI  
  30. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 2005; 65: 62-7. Neurology  
  31. Lewis CM, Suzuki M. Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Res Ther 2014; 5: 32. pmid:25157751 PubMed  
  32. Neudert C, Oliver D, Wasner M and Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248: 612-6. PubMed  
  33. Calvo A, Canosa A, Bertuzzo D, et al. Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1229-1233 . pmid:
  • Rune Midgard, dr. med., overlege og førsteamanuensis II emeritus, NTNU
  • Tor Andre Johannessen, lege og redaktør NEL

Tidligere fagmedarbeidere

  • Espen Dietrichs, professor og avdelingsoverlege, Universitetet i Oslo og Nevrologisk avdeling, Rikshospitalet, Oslo